glp-1 bowel obstruction legal team in louisiana Digger Earles Honored With Appointment to Plaintiff Steering Committee We often think of GLP-1s

Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.

Further research is warranted to explore long-term outcomes and optimize treatment protocols for this patient population

Is there a more American way to get 10k steps

An editorial review of Zealthy program model, medication options, eligibility, pricing, and editorial context

Weight loss drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) continue to have their moment in the medical space

Preclinical and preliminary clinical evidence of semaglutides potential beneficial effects on various substance use disorders led us to evaluate if it pertained to CUD